Publications by authors named "E Dailly"
Inulin, an increasingly studied dietary fiber, alters intestinal microbiota. The aim of this study was to assess whether inulin decreases intestinal colonization by multidrug resistant and to investigate its potential mechanisms of action. Mice with amoxicillin-induced intestinal dysbiosis mice were inoculated with extended spectrum beta-lactamase producing (ESBL-).
View Article and Find Full Text PDFArticle Synopsis
- - The study assessed XAV-19, an antibody treatment, for hospitalized COVID-19 patients with severe symptoms, focusing on its safety and effectiveness in preventing death or serious respiratory failure.
- - Conducted across 34 hospitals in France, the trial involved 398 adult patients who were randomly assigned to receive either XAV-19 or a placebo, with no major differences in outcomes observed between the two groups after 15 days.
- - Findings revealed that treatment with XAV-19 did not lead to a significant reduction in the incidence of severe health complications compared to placebo, and adverse events were similarly reported in both groups.
Objectives: Limited pharmacokinetics data support dalbavancin long-term use in off-label indications and the optimal dosing regimen is debated. We aimed to describe dalbavancin concentrations in an observational retrospective multicentre study.
Methods: Patients from 13 French hospitals, treated with 1500 mg doses of dalbavancin and for whom therapeutic drug monitoring was performed from June 2018 to March 2021 were included.
Aims: The main objective of this study was to compare extended-spectrum β-lactamase (ESBL) Escherichia coli fecal titers during 12 days between two groups: mice who received proton pump inhibitors (PPIs) and those that did not.
Methods And Results: We tested three different in vivo models: model 1, high inoculum (106 CFU ml-1); model 2, low inoculum (102 CFU ml-1); and model 3, low inoculum and 2-day amoxicillin wash-out. There was no significant difference between the two groups in fecal ESBL E.
Objective: We assessed the efficacy of a quality improvement programme to optimize the delivery of antimicrobial therapy in critically ill patients with hospital-acquired infections (HAI).
Patients And Methods: Before-after trial in a university hospital in France. Consecutive adults receiving systemic antimicrobial therapy for HAI were included.